Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma.
Xi ZhangLiqiong WangShu ChenPeng HuangLan MaHui DingBasappa BasappaTao ZhuPeter E LobieVijay PandeyPublished in: Communications medicine (2022)
A rational and efficacious combination strategy involving combined inhibition of pBADS99 and PARP for the treatment of recurrent EOC is presented.
Keyphrases